Ken Griffin Aeterna Zentaris Inc. Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.17 - $0.37 $2,690 - $5,855	-15,825 Reduced 8.27%	175,510 $35,000
Q4 2021 Feb 14, 2022	BUY	$0.36 - $0.77 $54,475 - $116,517	151,322 Added 378.18%	191,335 $68,000
Q3 2021 Nov 15, 2021	SELL	$0.59 - $0.88 $6,927 - $10,332	-11,741 Reduced 22.69%	40,013 $30,000
Q2 2021 Aug 16, 2021	BUY	$0.83 - $1.14 $15,869 - $21,796	19,120 Added 58.59%	51,754 $45,000
Q1 2021 May 17, 2021	BUY	$0.51 - $3.34 $16,643 - $108,997	32,634 New	32,634 $37,000
Q1 2020 May 15, 2020	SELL	$0.42 - $1.44 $4,969 - $17,038	-11,832 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$0.77 - $1.08 $2,510 - $3,521	-3,261 Reduced 21.61%	11,832 $11,000
Q3 2019 Nov 14, 2019	BUY	$1.0 - $2.97 $317 - $941	317 Added 2.15%	15,093 $15,000
Q2 2019 Aug 14, 2019	SELL	$2.04 - $5.43 $27,982 - $74,483	-13,717 Reduced 48.14%	14,776 $44,000
Q1 2019 May 15, 2019	BUY	$3.03 - $4.65 $36,363 - $55,804	12,001 Added 72.77%	28,493 $0
Q3 2018 Nov 13, 2018	BUY	$1.6 - $2.03 $10,142 - $12,868	6,339 Added 62.43%	16,492 $0
Q1 2018 May 11, 2018	BUY	$1.46 - $2.41 $14,823 - $24,468	10,153 New	10,153 $15,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.